Akrevia scoops ex-Arsanis chief René Russo as CEO; Scott Gottlieb jumps back into industry; Seattle Genetics raids AstraZeneca for CCO
→ Months after resigning from Arsanis — now relegated to biotech history books after a reverse merger with X4 Pharma — René Russo has landed her next CEO gig at Akrevia Therapeutics. The new role will shift her attention from anti-infectives to immuno-oncology, but she will lean on her experience scaling up biotech operations from an early stage. Backed by F-Prime Capital and Atlas Venture, Akrevia employs platform tech that packages a CTLA4 inhibitor in a way that the antibody would be inactive until it reaches the tumor microenvironment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.